Taken together, our data suggests that that TLR9 activation may be beneficial as co-treatment with current clinical LAM treatment, rapamycin, and may also be combined with checkpoint inhibitors for increased efficacy. This evidence concerns the gene TLR9 and lymphangioleiomyomatosis.